TEL : 0091-217-2310824
: 0091-217-2451500
FAX : 0091-217-2451521
E-MAIL : info@balajiamines.com
WEBSITE : http://www.balajiamines.com

Balaji

ISO 45001:2018
ISO 14001:2015
ISO 9001:2015
TÜV Rheinland CERTIFIED
www.tuv.com ID 9105038797

CIN : L24132MH1988PLC049387
AMINES LIMITED
... A Speciality Chemical Company
Regd. Off. : 'Balaji Towers' No. 9/1A /1,
Hotgi Road, Aasara Chowk, Solapur - 413 224.
Maharashtra. (India)

27th July, 2026

To,

The General Manager-Department of Corporate Services,	The Manager-Listing Department,
BSE Limited,	National Stock Exchange of India Limited,
Phiroze Jeejeebhoy Towers,	"Exchange Plaza", 5th Floor,
Dalal Street, Mumbai - 400 001.	Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051.
Scrip Code : 530999	**Symbol : BALAMINES**

Dear Sir/Madam,

Sub.: Press Release in connection with Un-audited Financial Results for the Quarter ended 30th June, 2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please enclosed herewith a copy of Press Release in connection with the Un-audited Financial Results for the Quarter ended 30th June, 2026.

The aforesaid information is also being made available on the website of the Company at https://www.balajiamines.com/investor-relations.php.

This is for your information and records.

Thanking you.

Yours faithfully,

For Balaji Amines Limited

ABHIJEET KOTHADIYA
Digitally signed by ABHIJEET KOTHADIYA
Date: 2026.07.27 19:16:57 +05'30'

Abhijeet Kothadiya
Company Secretary & Compliance Officer

Encl.: a/a

Investor Release **For Immediate Release**

Consolidated Q1FY27 Revenue stood at ₹ 461 Crore;

EBITDA stood at ₹ 121 Crore;

Net Profit stood at ₹ 78 Crore

Solapur, July 27, 2026: Balaji Amines Limited ("Company"), a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines, Ethyl Amines, Derivatives of Amines and other Speciality Chemicals, announced its unaudited financial results for the quarter ended June 30th, 2026.

Key Financial Highlights are as follows:

Particulars (₹ Cr.)	Standalone			Consolidated		
	Q1FY27	Q1FY26	Q4FY26	Q1FY27	Q1FY26	Q4FY26
Total Revenue (Rs. Cr)	**429**	**327**	**370**	**461**	**367**	**403**
EBITDA (Rs. Cr)	**110**	64	94	**121**	64	102
EBITDA Margin (%)	**26%**	**20%**	**26%**	**26%**	**17%**	**25%**
PAT (Rs. Cr)	**72**	40	62	**78**	37	65
PAT Margin (%)	**17%**	**12%**	**17%**	**17%**	**10%**	**16%**
Cash PAT* (Rs. Cr)	**89**	53	75	**97**	51	81
Cash PAT Margin (%)	**21%**	**16%**	**20%**	**20%**	**14%**	**20%**
Sales Volume (in MT)	**20,619**	**24,847**	**25,394**	**21,587**	**27,570**	**27,341**

***Cash PAT is PAT + Depreciation + Deferred tax*

Consolidated Performance Highlights for Q1 FY27

Revenue from Operations for Q1FY27 stood at ₹ 461 crore, as compared to ₹ 403 crore in Q4FY26, indicating stable operational performance. Volumes were maintained at similar levels last year, supported by stable commodity prices and consistent demand across key segments.

Total volumes stood at 21,587 MT for Q1 FY27 as against 27,570 MT in Q1 FY26.

For Q1FY27,

- Amines volumes stood at 6,248.57 MT
- Amines Derivatives volumes stood at 8,205.11 MT
- Specialty Chemicals volumes stood at 7,132.92 MT

EBITDA for Q1FY27 was ₹ 121 crore, as compared to ₹ 102 crore in Q4FY26 and ₹ 64 crore in Q1FY26.

EBITDA margin for Q1FY27 stood at 26%, as against 25% in Q4FY26 and 17% in Q1FY26.

PAT for Q1FY27 was ₹ 78 crore as compared to ₹ 65 crore in Q4FY26. **Diluted EPS** for Q1FY27 stood at ₹ 23.13 per equity share as against ₹ 19.99 in Q4FY26.

On a standalone basis, we are a zero-debt company.

Update on New Projects Commissioned and New Proposed Products/Projects

Following the successful commissioning of its 100,000 TPA Dimethyl Ether (DME) plant - India's first commercial-scale DME manufacturing facility - Balaji Amines continues to execute its growth roadmap with multiple projects under implementation. The DME plant marks the Company's strategic entry into alternate fuel applications, catering to LPG blending and aerosol propellant markets while strengthening its portfolio of new-age chemicals.

The Company's next phase of expansion includes the commissioning of N-Methyl Morpholine (NMM) and the Acetonitrile (ACN) capacity expansion during FY27, further broadening its specialty chemicals portfolio.

Balaji Speciality Chemicals – Next Phase of Growth

Balaji Speciality Chemicals Limited continues to advance its ₹750 crore phased expansion programme, which has been accorded Mega Project Status by the Government of Maharashtra under the Package Scheme of Incentives (PSI), 2019. The expansion is aimed at establishing an integrated specialty chemicals platform with the manufacture of high-value products including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN), EDTA, EDTA-2Na, and downstream EDA derivatives such as DETA, TETA, Piperazine (PIP), AEEA and AEP.

The project represents a significant step in building indigenous capabilities in cyanide chemistry, enabling domestic production of critical intermediates that currently rely on imports, particularly for the pharmaceutical, agrochemical and mining industries.

Execution of the expansion is progressing as planned.

a)The brownfield Unit-I expansion for EDA-based downstream products is expected to be commissioned during FY27.

b) The greenfield Unit-II facility at MIDC Chincholi is under execution, with plants for HCN, NaCN, EDTA and EDTA-2Na targeted for commissioning during FY27.

On the performance, Mr. D. Ram Reddy, Managing Director, commented, [NS1]

We have commenced FY27 on a strong note, delivering healthy operational and financial performance supported by improved demand across key end-user industries and sustained execution across our businesses. Our diversified product portfolio, integrated manufacturing capabilities and strong customer relationships enabled us to effectively capitalize on operational efficiencies. This has been the leveraging point with improving market conditions while maintaining sustainable performance in the adverse scenarios of West Asia's crisis.

During the quarter, we achieved a significant milestone with the successful commissioning of India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant. This marks an important milestone in BAL's strategic vision to diversify into new-age chemicals and alternate fuel applications, while reinforcing our commitment towards import substitution and creating long-term value chain for our customers.

We continue to make steady progress on our growth pipeline with the Expansion Projects viz. N-Methyl Morpholine (NMM), Acetonitrile (ACN) projects. Further, the expansion plans of Balaji Speciality Chemicals Limited are progressing as planned and are expected to further strengthen our group's product portfolio over the coming quarters.

Our integrated manufacturing platform continues to be a key competitive advantage, providing operational flexibility, supply chain reliability and cost efficiencies across product lines. At the same time, we remain focused on expanding our presence in high-value specialty chemicals and electronic-grade products, positioning the Company to benefit from structural growth opportunities in pharmaceuticals, agrochemicals, alternate fuels and the evolving EV battery chemicals ecosystem.

Looking ahead, we remain confident in our growth outlook. Backed by a healthy order pipeline, improving demand environment, ongoing capacity additions and a disciplined approach to execution, we at Balaji Amines are well positioned to deliver sustainable growth in all its endeavors in the coming years.

About Balaji Amines Limited (BAL)

Balaji Amines Ltd (BAL), set up in 1988, is a leading manufacturer of Aliphatic Amines in India. Broadly, the company is specialised in manufacturing Methyl Amines, Ethyl Amines, Derivatives of Aliphatic Amines and Specialty Chemicals. Its business is broadly classified into three segments - Amines, Specialty Chemicals and Derivatives. BAL commenced manufacturing of Methyl Amines in 1990, and later added facilities of Ethyl Amines and other derivatives of Methyl amines and Ethyl amines. The company enjoys leadership position in many of its products like Monomethylamine (MMA), Dimethyl amine (DMA), Trimethylamine (TMA), Dimethyl Amino Ethanol (DMAE), Mono Methyl Amino Ethanol etc.

It caters to a host of industries like Pharma, Agro Chemicals, Paint Stripping & Resins, Rubber cleaning chemicals etc. The company has four state of the art manufacturing sites – three near Solapur and one near Hyderabad. In addition, BAL possesses a fully furnished Laboratory which helps the company in development of newer products. A majority of its products are being exported to major customers worldwide and the company has become one of the leaders in Specialty Chemicals among the International Specialty Chemical players. The company also operates a 5-star hotel in Solapur – Balaji Sarovar. It has tied up with Sarovar group for management of this hotel.

For more information, please visit www.balajiamines.com

Safe Harbor Statement

Company	Investor Relations Advisors
Balaji Amines Limited CIN No: L24132MH1988PLC049387 Email id: cs@balajiamines.com	**MUFG Intime India Private Limited** Mr. Nikunj Seth: +91 9773397958 nikunj.seth@in.mpms.mufg.com Ms. Sakshi Mehta: +91 9833212052 sakshi.mehta@in.mpms.mufg.com